2.55Open2.55Pre Close0 Volume1 Open Interest175.00Strike Price0.00Turnover127.41%IV31.84%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry2.55Extrinsic Value100Contract SizeAmericanOptions Type-0.0720Delta0.0019Gamma99.22Leverage Ratio-0.2699Theta-0.0093Rho-7.14Eff Leverage0.0764Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet